Cargando…

Bioequivalence of Olanzapine Given in Combination With Samidorphan as a Bilayer Tablet (ALKS 3831) Compared With Olanzapine‐Alone Tablets: Results From a Randomized, Crossover Relative Bioavailability Study

The objective of this study was to evaluate the relative bioavailability of olanzapine in 3 olanzapine‐containing tablet formulations. ALKS 3831 is a fixed‐dose combination of olanzapine (OLZ, an atypical antipsychotic) and samidorphan (SAM, a μ‐opioid receptor antagonist with low intrinsic activity...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Lei, McDonnell, David, Liu, Jianjun, von Moltke, Lisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585851/ https://www.ncbi.nlm.nih.gov/pubmed/30059196 http://dx.doi.org/10.1002/cpdd.601

Ejemplares similares

Effect of hepatic and renal impairment on the pharmacokinetics of olanzapine and samidorphan given in combination as a bilayer tablet
por: Sun, Lei, et al.
Publicado: (2019)

Using physiologically‐based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet
por: Sun, Lei, et al.
Publicado: (2021)

Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effect of Renal Impairment on the Pharmacokinetics of Olanzapine and Samidorphan Given in Combination
por: Sun, Lei, et al.
Publicado: (2020)

S226. A STUDY COMPARING WEIGHT GAIN FROM ALKS 3831 TO OLANZAPINE IN EARLY-ILLNESS YOUNG ADULTS WITH SCHIZOPHRENIFORM, SCHIZOPHRENIA, OR BIPOLAR I DISORDER
por: Simmons, Adam, et al.
Publicado: (2018)

Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers
por: Toledo, Frederico G. S., et al.
Publicado: (2021)

Combination of Olanzapine and Samidorphan Has No Clinically Significant Effect on the Pharmacokinetics of Lithium or Valproate
por: Sun, Lei, et al.
Publicado: (2019)

Physiologically‐Based Pharmacokinetic Modeling for Predicting Drug Interactions of a Combination of Olanzapine and Samidorphan
por: Sun, Lei, et al.
Publicado: (2020)

The Facts and Fiction of Olanzapine-Samidorphan Fixed Dose Combination
por: Das, Nileswar, et al.
Publicado: (2022)

Effectiveness and medication acceptance of olanzapine disintegrating tablets compared to standard olanzapine tablets in acutely treated psychiatric patients
por: Czekalla, Jörg, et al.
Publicado: (2007)

A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine
por: Srisurapanont, Manit, et al.
Publicado: (2021)

Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study
por: Bitter, Istvan, et al.
Publicado: (2010)

Assessment of the stability of co-amorphous olanzapine in tablets
por: da Costa, Nuno F., et al.
Publicado: (2021)

Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study
por: Correll, Christoph U, et al.
Publicado: (2022)

Evaluation of Bioequivalence of Two Oral Formulations of Olanzapine
por: Singhal, R., et al.
Publicado: (2011)

Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia
por: Sun, Lei, et al.
Publicado: (2021)

Combining samidorphan with olanzapine to mitigate weight gain as a side effect in schizophrenia treatment
por: Grywińska, Weronika B., et al.
Publicado: (2023)

Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates
por: Cunningham, Jacobi I, et al.
Publicado: (2019)

Effects of Combined Therapy of Olanzapine and Samidorphan on Safety and Metabolic Parameters in Schizophrenia Patients: A Meta-Analysis
por: Peng, Zhenlei, et al.
Publicado: (2023)

Simultaneous RP-HPLC and HPTLC Estimation of Fluoxetine Hydrochloride and Olanzapine in Tablet Dosage Forms
por: Patel, Sejal, et al.
Publicado: (2009)

Stability-indicating Simultaneous HPTLC Method for Olanzapine and Fluoxetine in Combined Tablet Dosage Form
por: Shah, C. R., et al.
Publicado: (2008)

Characterization of the Pharmacokinetics of Samidorphan in Healthy Volunteers: Absolute Bioavailability and the Effect of Food and Age
por: Kumar, Vipul, et al.
Publicado: (2019)

Bioequivalence and Bioavailability of an Orodispersible Tablet of Sildenafil Citrate in Healthy Chinese Male Subjects
por: Lv, Yuan, et al.
Publicado: (2020)

The gut microbiome influences the bioavailability of olanzapine in rats
por: Cussotto, Sofia, et al.
Publicado: (2021)

Bioequivalence of Esaxerenone Conventional Tablet and Orally Disintegrating Tablet: Two Single‐Dose Crossover Studies in Healthy Japanese Men
por: Kurata, Akifumi, et al.
Publicado: (2022)

Samidorphan/olanzapine combination therapy for schizophrenia: Efficacy, tolerance and adverse outcomes of regimen, evidence-based review of clinical trials
por: Rehan, Syeda Tayyaba, et al.
Publicado: (2022)

F232. A PHASE 3 STUDY TO DETERMINE THE ANTIPSYCHOTIC EFFICACY AND SAFETY OF ALKS 3831 IN ADULT PATIENTS WITH ACUTE EXACERBATION OF SCHIZOPHRENIA
por: McDonnell, David, et al.
Publicado: (2018)

An In Vitro Analysis of Disintegration Times of Different Formulations of Olanzapine Orodispersible Tablet: A Preliminary Report
por: Hobbs, David, et al.
Publicado: (2013)

Bioequivalence of macitentan and tadalafil given as fixed‐dose combination or single‐component tablets in healthy subjects
por: Grill, Simon, et al.
Publicado: (2020)

Pharmacokinetics and Bioequivalence Evaluation of Cyclobenzaprine Tablets
por: Brioschi, Tatiane Maria de Lima Souza, et al.
Publicado: (2013)

Formulation and In-vitro Evaluation of Orally Disintegrating Tablets of Olanzapine-2-Hydroxypropyl-β-Cyclodextrin Inclusion Complex
por: Ajit Shankarrao, Kulkarni, et al.
Publicado: (2010)

Comparison of clinical outcomes with orodispersible versus standard oral olanzapine tablets in nonadherent patients with schizophrenia or bipolar disorder
por: Novick, Diego, et al.
Publicado: (2017)

Bioavailability, pharmacokinetics and safety of riociguat given as an oral suspension or crushed tablet with and without food
por: Saleh, Soundos, et al.
Publicado: (2015)

Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer
por: Babiker, Hani M., et al.
Publicado: (2020)

Pharmacovigilance on olanzapine
por: Lingeswaran, Anand, et al.
Publicado: (2010)

Teratogenicity with Olanzapine
por: Prakash, Sathya, et al.
Publicado: (2014)

Comparative Bioequivalence of Tablet and Capsule Formulations of Ulotaront and the Effect of Food on the Pharmacokinetics of the Tablet Form in Humans
por: Chen, Yu-Luan, et al.
Publicado: (2023)

Effects of food on pharmacokinetics and safety of metformin hydrochloride tablets: A meta-analysis of pharmacokinetic, bioavailability, or bioequivalence studies
por: Sun, Ming-Li, et al.
Publicado: (2023)

A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future
por: Citrome, Leslie, et al.
Publicado: (2019)

Determination of Olanzapine and N-desmethyl-olanzapine in Plasma Using a Reversed-Phase HPLC Coupled with Coulochemical Detection: Correlation of Olanzapine or N-desmethyl-olanzapine Concentration with Metabolic Parameters
por: Lu, Mong-Liang, et al.
Publicado: (2013)

Bioequivalence of saxagliptin/dapagliflozin fixed‐dose combination tablets compared with coadministration of the individual tablets to healthy subjects
por: Vakkalagadda, Blisse, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0nl4ov8qnehm60i20frne3pkpr